Cystotech key facts
as of Oct 2026- Developer of an artificial intelligence-based support technology designed to transform the future of bladder cancer treatment.
- Cystotech is valued at approximately $11.1M as of Oct 2026 (last reported valuation).
- It has raised $5.5M; the latest was Later Stage VC ($1.9M) in Jan 2026.
- Notable investors include InnoFounder, Denmark's Export and Investment Fund, CancerX (USA), Aarhus University, Danish Business Angels — 7 tracked in total.
- Status: Privately Held (backing).
Cystotech's last reported valuation, May 2025. Nothing priced has surfaced since.
- ·Watch Cystotech: the Monday email on marks, rounds and moves
Cystotech funding rounds
No funding rounds for Cystotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Cystotech valuation
Cystotech's last reported valuation was $11.1 million in May 2025. No priced round, secondary trade or fund mark has surfaced since.
Cystotech investors
7 investors are on record for Cystotech, including InnoFounder, Denmark's Export and Investment Fund, CancerX (USA) and Aarhus University.
About Cystotech
Developer of an artificial intelligence-based support technology designed to transform the future of bladder cancer treatment. The company's technology focuses is on changing clinical practice, favoring patient outcomes and driving healthcare toward improved personalised treatment, enabling healthcare professionals and organizations to focus on diagnostic performance and the use of less invasive approaches to treatment for the benefit of patients and healthcare costs.
- Sector
- Healthcare
- HQ
- Aarhus Centrum, Denmark
- Founded
- 2021
- Employees
- 20
- Website
- cystotech.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.